Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.40 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093355 | 0.87 | ADORA3 (0.44) | TP53ADORA3ADORA1KMT5BKMT5C | |
| SCHEMBL1093851 | 0.83 | ADORA3 (0.57) | TP53ADORA3ADORA1CNR1SMN1; SMN2 | |
| SCHEMBL1093673 | 0.79 | ADORA3 (0.53) | TP53ADORA3ADORA1CNR1SMN1; SMN2 | |
| SCHEMBL1094153 | 0.75 | CNR1 (0.43) | CNR1SMN1; SMN2CNR2DGAT2 | |
| SCHEMBL1093738 | 0.74 | LMNA (0.47) | SMN1; SMN2LMNA | |
| SCHEMBL1093967 | 0.73 | MAPT (0.47) | TP53LMNA | |
| SCHEMBL1093154 | 0.72 | ADORA3 (0.55) | TP53ADORA3ADORA1SMN1; SMN2ADORA2A | |
| SCHEMBL1093721 | 0.71 | CNR1 (0.42) | CNR1SMN1; SMN2CNR2DGAT2LMNA | |
| SCHEMBL1093235 | 0.71 | ADORA3 (0.45) | TP53ADORA3ADORA1SMN1; SMN2ALOX5 | |
| SCHEMBL2170815 | 0.70 | EPHX1 (0.53) | ADORA3CNR1SMN1; SMN2CNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346834-B1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8153663-B2 | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| CN-102164900-A | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | disclosed |
| EP-2346834-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010034657-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100076026-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076026-A1 | 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES | NR1H4, SLC10A2, SLC10A1 | TP53 4192/4885ADORA3 11/4885ADORA1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.